| abstract |
Provided herein are biomarker proteins in which changes in their concentration or activity level are associated with clinically significant treatment of atypical hemolytic uremic syndrome (aHUS) or aHUS with complement inhibitors. Compositions and methods are also provided for examining the concentration and/or activity of one or more biomarker proteins in a biological fluid. The compositions and methods are, inter alia, assessing the risk of developing aHUS and/or diagnosing aHUS and/or determining whether a subject undergoes the first acute signs of aHUS, and/or monitoring progression or remission of aHUS, and/or It is useful to monitor response to treatment with inhibitors or to optimize such treatment. |